<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380873</url>
  </required_header>
  <id_info>
    <org_study_id>CJ_VCM_103</org_study_id>
    <nct_id>NCT01380873</nct_id>
  </id_info>
  <brief_title>A Pharmacodynamic Study of SLM0807, HKB0701 and CJ30001 in Healthy Subject</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>CJ HealthCare Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CJ HealthCare Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted to

        1. assess whether SLM0807 alters pharmacodynamics of HKB0701

        2. estimate the pharmacodynamics of HKB0701 after multiple administration of CJ30001 and
           multiple co-administration of HKB0701/SLM0807 in healthy subject
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0-2h of plasma glucose</measure>
    <time_frame>up to 2hrs</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>△Cmax of plasma glucose</measure>
    <time_frame>up to 2hrs</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001</intervention_name>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701</intervention_name>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807</intervention_name>
    <arm_group_label>Group3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy volunteers who are in age range of 20-50years and the weight range is not
             exceed ±20% of ideal weight. Ideal weight = [height -100]*0.9

          -  Subjects with no history of any significant chronic disease

          -  Subjects with FPG&lt;100mg/dL and 2hr glucose after 75g OGTT&lt;140mg/dL

          -  Judged to be in good health on the basis of their vital sign, ECG, physical exam and
             routine laboratory data

          -  Available for the entire study period

          -  Willing to adhere to protocol requirements and sign a informed consent form

        Exclusion Criteria:

          -  Subjects who have taken any drugs to induce or inhibit hepatic enzyme activity within
             30days prior to drug administration

          -  Subjects who have symptom of an acute illness within 4 weeks prior to drug
             administration

          -  Subjects with a history of clinically significant allergies including drug allergies

          -  Subjects whose clinical laboratory test values are outside the accepted normal
             range(Especially,AST or ALT &gt;1.25 times to normal range or total bilirubin &gt; 1.5times
             to normal range)

          -  Subjects with a history of drug, caffeine abuse(caffeine drink &gt;5cups/day)

          -  Subjects with a history of alcohol abuse(alcohol&gt;30g/day) or who have ever drank
             alcohol within 7 days prior to drug administration

          -  Heavy smoker ( &gt;10cigarettes/day)

          -  Subjects who have had a diet known to interfere with the absorption, distribution,
             metabolism or excretion of drugs (especially, consumption of grapefruit juice)

          -  Subjects who have donated plasma within 60days prior to drug administration

          -  Subjects who have participated in a clinical study within 90days prior to drug
             administration

          -  Subjects who have received any drugs that might confound the results of the trial in
             the opinion of principal investigator within 10days prior to drug administration
             (cimetidine within 7days prior to drug administration)

          -  Female subjects who are pregnant, breastfeeding or not using medically acceptable
             birth control
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae Gook Shin, MD, ph D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Inje University</affiliation>
  </overall_official>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Geun Seog, Song / Director of Regulatory and Clinical Development</name_title>
    <organization>CJ Cheiljedang Corporation</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

